Zobrazeno 1 - 10
of 648
pro vyhledávání: '"Masafumi Taniwaki"'
Autor:
Yuka Kawaji-Kanayama, Taku Tsukamoto, Masakazu Nakano, Yuichi Tokuda, Hiroaki Nagata, Kentaro Mizuhara, Yoko Katsuragawa-Taminishi, Reiko Isa, Takahiro Fujino, Yayoi Matsumura-Kimoto, Shinsuke Mizutani, Yuji Shimura, Masafumi Taniwaki, Kei Tashiro, Junya Kuroda
Publikováno v:
HemaSphere, Vol 7, p e0595036 (2023)
Externí odkaz:
https://doaj.org/article/7f65d70361e148a7b17fa48f78cdaf49
Autor:
Yayoi Matsumura‐Kimoto, Taku Tsukamoto, Yuji Shimura, Yoshiaki Chinen, Kazuna Tanba, Saeko Kuwahara‐Ota, Yuto Fujibayashi, Daichi Nishiyama, Reiko Isa, Junko Yamaguchi, Yuka Kawaji‐Kanayama, Tsutomu Kobayashi, Shigeo Horiike, Masafumi Taniwaki, Junya Kuroda
Publikováno v:
Cancer Medicine, Vol 9, Iss 14, Pp 5185-5199 (2020)
Abstract RSK2 is a serine/threonine kinase downstream signaling mediator in the RAS/ERK signaling pathway and may be a therapeutic target in mantle cell lymphoma (MCL), an almost incurable disease subtype of non‐Hodgkin lymphoma. In this study, ser
Externí odkaz:
https://doaj.org/article/9e1e7146637b4917811ff4b9c406b974
Autor:
Yuka Kawaji‐Kanayama, Tsutomu Kobayashi, Ayako Muramatsu, Hitoji Uchiyama, Nana Sasaki, Nobuhiko Uoshima, Mitsushige Nakao, Ryoichi Takahashi, Kazuho Shimura, Hiroto Kaneko, Miki Kiyota, Katsuya Wada, Yoshiaki Chinen, Koichi Hirakawa, Shin‐ichi Fuchida, Chihiro Shimazaki, Yayoi Matsumura‐Kimoto, Shinsuke Mizutani, Taku Tsukamoto, Yuji Shimura, Shigeo Horiike, Masafumi Taniwaki, Junya Kuroda, Kyoto Clinical Hematology Study Group (KOTOSG) Investigators
Publikováno v:
Cancer Reports, Vol 5, Iss 2, Pp n/a-n/a (2022)
Abstract Background Combinatory strategies with carfilzomib (CFZ), a second‐generation proteasome inhibitor, plus dexamethasone (DEX) with or without lenalidomide (LEN) have shown promising efficacy for patients with relapsed/refractory multiple my
Externí odkaz:
https://doaj.org/article/bdff3f7ce0164c809dccfaff7fdd38f3
Autor:
Hiroto Kaneko, Kazuho Shimura, Mihoko Yoshida, Yosuke Matsumoto, Tsutomu Kobayashi, Hitoji Uchiyama, Junya Kuroda, Masafumi Taniwaki
Publikováno v:
International Journal of Hematology-Oncology and Stem Cell Research, Vol 16, Iss 1 (2022)
Background: In the current Japanese aging society, a high number of very elderly patients (age ranged from 80 to 93) with diffuse large B-cell lymphoma (DLBCL, most frequent hematological malignancy), who require chemotherapy are encountered. However
Externí odkaz:
https://doaj.org/article/1c2ccacab0fe45878d64dbf7d7152a85
Autor:
Shohei Mizuno, Ichiro Hanamura, Akinobu Ota, Sivasundaram Karnan, Jo Kanasugi, Ayano Nakamura, Souichi Takasugi, Kaori Uchino, Tomohiro Horio, Mineaki Goto, Satsuki Murakami, Mayuko Gotou, Hidesuke Yamamoto, Masaya Watarai, Masato Shikami, Yoshitaka Hosokawa, Hiroshi Miwa, Masafumi Taniwaki, Ryuzo Ueda, Masakazu Nitta, Akiyoshi Takami
Publikováno v:
FEBS Open Bio, Vol 8, Iss 12, Pp 1977-1991 (2018)
Chromosome band 8q24 is the most frequently amplified locus in various types of cancers. MYC has been identified as the primary oncogene at the 8q24 locus, whereas a long noncoding gene, PVT1, which lies adjacent to MYC, has recently emerged as anoth
Externí odkaz:
https://doaj.org/article/fce41036b929420d9e501181a4ef1468
Autor:
Yoshimi Mizuno, Taku Tsukamoto, Eri Kawata, Nobuhiko Uoshima, Hitoji Uchiyama, Isao Yokota, Saori Maegawa, Tomoko Takimoto, Kazuna Tanba, Yayoi Matsumura‐Kimoto, Saeko Kuwahara‐Ota, Yuto Fujibayashi, Mio Yamamoto‐Sugitani, Yoshiaki Chinen, Yuji Shimura, Shigeo Horiike, Masafumi Taniwaki, Tsutomu Kobayashi, Junya Kuroda
Publikováno v:
Cancer Medicine, Vol 7, Iss 3, Pp 655-664 (2018)
Abstract Diffuse large B‐cell lymphoma (DLBCL), which is the most prevalent disease subtype of non‐Hodgkin lymphoma, is highly heterogeneous in terms of cytogenetic and molecular features. This study retrospectively investigated the clinical impa
Externí odkaz:
https://doaj.org/article/5970ece3c6544cbb98a7014cb94e5845
Autor:
Masafumi Taniwaki, Mihoko Yoshida, Yosuke Matsumoto, Kazuho Shimura, Junya Kuroda, Hiroto Kaneko
Publikováno v:
Mediterranean Journal of Hematology and Infectious Diseases, Vol 10, Iss 1, Pp e2018014-e2018014 (2018)
Elotuzumab, targeting signaling lymphocytic activation molecule family 7 (SLAMF7), has been approved in combination with lenalidomide and dexamethasone (ELd) for relapsed/refractory multiple myeloma (MM) based on the findings of the phase III randomi
Externí odkaz:
https://doaj.org/article/c29b13fc01f34a618bb25d06f8b63492
Autor:
Kensuke Matsuda, Yosuke Matsumoto, Mihiko Yoshida, Kazuho Shimura, Hiroto Kaneko, Tohru Inaba, Shigeo Horiike, Junya Kuroda, Masafumi Taniwaki
Publikováno v:
Mediterranean Journal of Hematology and Infectious Diseases, Vol 9, Iss 1, Pp e2017054-e2017054 (2017)
Hairy B-cell lymphoproliferative disorder (HBLD) is one of chronic polyclonal B-cell lymphocytosis. We report a 47-year-old female Japanese patient diagnosed as having HBLD based on lymphocytosis with hairy cell appearance and characteristic phenotyp
Externí odkaz:
https://doaj.org/article/0231e8b933714b3e86d0d24131334463
Autor:
Yuji Shimura, Junya Kuroda, Nana Sasaki, Hitoji Uchiyama, Muneo Ohshiro, Yayoi Matsumura, Hisao Nagoshi, Shinsuke Mizutani, Tsutomu Kobayashi, Yosuke Matsumoto, Shigeo Horiike, Masafumi Taniwaki
Publikováno v:
Case Reports in Oncology, Vol 7, Iss 1, Pp 188-194 (2014)
A 54-year-old male was diagnosed with follicular lymphoma in September 2003. Despite multiple chemotherapies, including autologous hematopoietic stem cell transplantation (HSCT) with high-dose chemotherapy, the disease eventually relapsed. Additional
Externí odkaz:
https://doaj.org/article/e07bf64010214add88bf820430ee1266
Autor:
Hiroto Kaneko, Yasuhiko Tsutsumi, Takahiro Fujino, Saeko Kuwahara, Muneo Ohshiro, Toshiki Iwai, Junya Kuroda, Shouhei Yokota, Shigeo Horiike, Masafumi Taniwaki
Publikováno v:
Hematology Reports, Vol 7, Iss 2 (2015)
High-dose chemotherapy followed by autologous stem cell transplantation (ASCT) has been applied to patients with diffuse large B-cell lymphoma (DLBCL); it is well established that ASCT shows significant survival benefits for chemosensitive relapse. H
Externí odkaz:
https://doaj.org/article/9a14a24337574bea99e0e075b6bdcffe